BTIG reaffirmed its "Buy" rating for NASDAQ:ABVX, increasing the price target from $112 to $120.Abivax's experimental drug, obefazimod, shows promising results in treating ulcerative colitis, leading to remission in patients unresponsive to previous therapies.The drug's success boosts its strategic appeal, indicating strong interest from larger pharmaceutical companies amid rising mergers and acquisitions.Abivax (NASDAQ:ABVX) is a prominent biotech company known for its innovative treatments in the field of ...

PresentationI would now like to hand the conference over to your speaker today, Pat Malloy. Please go ahead.Good day, and thank you for standing by. Welcome to the ABIVAX management call to discuss late-breaking ABTECT at UEG Conference. [Operator Instructions] Please be advised that today's conference is being recorded.Patrick MalloySenior Vice President of Investor Relations Great. Thank you, Sandra, and good morning and good afternoon to everybody, and thank you for joining today's call to discuss the re ...

Luxury carmaker Aston Martin on Monday warned of a deepening annual loss due to weaker than expected demand in North America and Asia Pacific and the impact of US tariffs, sending shares 10% lower.The company said that its annual loss will now exceed 110 million pounds ($147.81 million), marking a sharp deterioration from July, when Aston Martin first warned that tariffs had been “extremely disruptive” and forecast adjusted operating profit would roughly break even this year compared with earlier expectatio ...

临床试验数据更新 - 公司在UEG会议上公布了obefazimod的3期ABTECT 8周诱导试验额外临床数据[1] - 试验针对中重度活动性溃疡性结肠炎患者共入组1272名患者[1] 药物疗效结果 - 每日一次50mg obefazimod在所有亚组中均实现临床意义的改善包括既往有高级疗法应答不足患者[2] - 在无既往AT-IR患者中临床应答的安慰剂校正差异为28%在有最多四个或以上既往AT-IR患者中差异为29%[2] - 在既往JAK抑制剂治疗失败患者中临床应答的安慰剂校正差异达到34%[3] - 无论既往AT-IR状态如何药物在内镜和组织学终点上均实现临床意义的改善[3] - 对于无既往AT-IR患者25mg和50mg每日一次剂量在临床内镜和组织学终点上显示出相似疗效[4] 试验主要终点与安全性 - 两项试验中每日一次50mg剂量方案在第8周均达到FDA主要终点临床缓解[5] - ABTECT-1试验显示50mg剂量临床缓解率的安慰剂校正差异为193% ABTECT-2试验为134%[6] - 所有关键次要疗效终点均被满足[6] - 药物持续表现出良好耐受性未发现新的安全性信号[4] - 未观察到严重重度或机会性感染及恶性肿瘤的信号[5] 市场反应 - 公司股价在数据公布后上涨571%至8872美元[6]

ABIVAX (NasdaqGM:ABVX) Conference October 06, 2025 09:00 AM ET Speaker0Good day and thank you for standing by. Welcome to the Abibag's management call to discuss late breaking abstract at UEG conference. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.You will then hear an automated message advising your hand is raised. Please be advised t ...

Abivax Investor and Analyst Webcast October 6, 2025 HBIVHX Marla Dubinsky, MD Co-Director of the Susan and Leonard Feinstein IBD Clinical Center . Dr. Dubinsky is a paid consultant for Abivax 2 HBIVAX Opening Remarks UEG Data Overview Q&A Pat Malloy Senior Vice President, Investor Relations Marc de Garidel Chief Executive Officer Marla Dubinsky, M.D. Abivax Leadership & Marla Dubinsky, M.D. ■ Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai ■ Chief of Pediatric Gastroenter ...

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in participants with and without prior inadequate response to up to 4+ lines of advanced ther ...

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and all key secondary endpoints in both ABTECT 1 and ABTECT 2ABTECT trials enrolled refractory patient population with 47% of participants having prior inadequate response to advanced therapy, among whom 21% had prior inadequate response to JAK inhibitor therapyObefazimod treatm ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. ABIVAX Société Anonyme is one of them. ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology company developing therapies to regulate immune responses in chronic inflammatory diseases. Its lead candidate, obefazimod (ABX464), is an oral miR-124 enhancer currently in Phase 3 trials for ulcerative colitis (UC) and Phase 2b trials for Crohn’s disease. In September 2025, ABVX announced it would present ...

Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO, PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 8-WEEK INDUCTION TRIALS (ABTECT-1 & 2) to be presented Sunday, October 5 at 5pm CEST PARIS, France – September 29, 2025 – 10:05 PM ...